Given the early, promising bioactivity profile of mandelalides A and B against LKB1-null NCI-H460 lung cancers cells [1], yet differential sensitivity of cells comprising the NCI-60 lung cancer cell panel [4], we investigated AMPK signaling and growth characteristics of NSCLC cells with differing LKB1 status. The gene discussed is PRKAA2; the disease is non-small cell lung carcinoma.